DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027
Source: SeekingAlpha
2025-11-13 10:02:08 ET
More on DiaMedica Therapeutics
- DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript
- DiaMedica Therapeutics GAAP EPS of -$0.17 misses by $0.01
- Seeking Alpha’s Quant Rating on DiaMedica Therapeutics
- Historical earnings data for DiaMedica Therapeutics
- Financial information for DiaMedica Therapeutics
Read the full article on Seeking Alpha
For further details see:
DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027
DiaMedica Therapeutics Inc.
NASDAQ: DMAC
DMAC Trading
-3.43% G/L:
$7.61 Last:
48,560 Volume:
$7.61 Open:
DMAC Latest News
March 05, 2026 07:35:00 am
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
February 24, 2026 09:23:00 am
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
January 16, 2026 05:00:00 pm
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2025 08:45:00 am
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
DMAC Stock Data
$439,533,585
29,684,140
16.95%
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Minneapolis
